Delta-Omicron recombinant SARS-CoV-2 in a transplant patient treated with Sotrovimab

Ralf Duerr; Hao Zhou; Takuya Tada; Dacia Dimartino; Christian Marier; Paul Zappile; Guiqing Wang; Jonathan Plitnick; Sara Griesemer; Roxie C. Girardin; Jessica Machowski; Sean Bialosuknia; Erica Lasek-Nesselquist; Samuel L Hong; Guy Baele; Meike Dittman; Mila Brum Ortigoza; Prithiv J. Prasad; Kathleen McDonough; Nathaniel Landau; Kirsten St. George; Adriana Heguy.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-487325

Documentos relacionados

  1. Delta-Omicron recombinant escapes therapeutic antibody neutralization.
  2. Delta-Omicron recombinant escapes therapeutic antibody neutralization.
  3. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike.
  4. Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.
  5. Evaluating mAbs binding abilities to Omicron subvariant RBDs: implications for selecting effective mAb therapies.
  6. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
  7. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron.
  8. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
  9. T cell responses to SARS-CoV-2 spike cross-recognize Omicron.
  10. A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant.